UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000021461
Receipt number R000024746
Scientific Title A prospective cohort study of efficacy and safety by methods of the procedure of transcatheter arterial chemoembolization with hepatocellular carcinoma.
Date of disclosure of the study information 2016/03/13
Last modified on 2016/03/13 16:54:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A prospective cohort study of efficacy and safety by methods of the procedure of transcatheter arterial chemoembolization with hepatocellular carcinoma.

Acronym

A prospective cohort study of efficacy and safety by methods of the procedure of transcatheter arterial chemoembolization with hepatocellular carcinoma.

Scientific Title

A prospective cohort study of efficacy and safety by methods of the procedure of transcatheter arterial chemoembolization with hepatocellular carcinoma.

Scientific Title:Acronym

A prospective cohort study of efficacy and safety by methods of the procedure of transcatheter arterial chemoembolization with hepatocellular carcinoma.

Region

Japan


Condition

Condition

hepatocellular carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficacy and safety by methods of the procedure of transcatheter arterial chemoembolization with hepatocellular carcinoma.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Antitumor effect of each nodule after 3 months of TACE

Key secondary outcomes

Response rate
Time to Progression
Overall Survival
Incidence rate of adverse events
severity of vascular damage


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Presence of histologically confirmed or clinically diagnosed hepatocellular carcinoma
2) At least 1 target lesion measurable
3) 20 years or more
4) Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 2
5) Child-Pugh classification A or B
6) Life expectancy of at least 12 weeks
7) Written informed consent

Key exclusion criteria

1) Cre <= ULN x 1.5
2) Severe cardiac disease
3) Severe cerebrovascular disease
4) interstitial pneumoniae
5) Active infection(except HBV and HCV infection)
6) Dynamic CT or EOB-MRI cannot be performed
7) Pregnant or lactating woman
8) Any patients judged by the investigator to be unfit to participate in the study

Target sample size

225


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Osamu Yokosuka

Organization

Chiba University Hospital

Division name

Department of Gastroenterology

Zip code


Address

1-8-1 Inohana, Chuou-ku, Chiba

TEL

043-222-7171

Email

yokosukao@faculty.chiba-u.jp


Public contact

Name of contact person

1st name
Middle name
Last name WakamatsuToru

Organization

Chiba University Hospital

Division name

Department of Gastroenterology

Zip code


Address

1-8-1 Inohana, Chuou-ku, Chiba

TEL

043-222-7171

Homepage URL


Email

t_wakamatsu_3333@yahoo.co.jp


Sponsor or person

Institute

Chiba University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 03 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2015 Year 07 Month 31 Day

Date of IRB


Anticipated trial start date

2015 Year 08 Month 31 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

To compare efficacy and safety between patients treated with Baloon-occluded TACE, drug eluting bead (DEB)-TACE (non baloon-occluded) and DEB-TACE (baloon-occluded).


Management information

Registered date

2016 Year 03 Month 13 Day

Last modified on

2016 Year 03 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024746


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name